Trends in white blood cell and platelet indices in a comparison of patients with papillary thyroid carcinoma and multinodular goiter do not permit differentiation between the conditions

References

• Giraldo NA, Becht E, Vano Y, Sautès-Fridman C, Fridman WH. The immune response in cancer: From immunology to pathology to immunotherapy. Virchows Arch. 2015;467:127–135.
   PubMed Web of Science ®Google Scholar
• Wu Y, Fu X, Zhu X, et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: A systematic review and meta-analysis. J Cancer Res Clin Oncol. 2011;137:887–896.
   PubMed Web of Science ®Google Scholar
• Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: A casual or causal relationship: Revisited. Cancer Metastasis Rev. 2014;33:231–269.
   PubMed Web of Science ®Google Scholar
• Yan M, Jurasz P. The role of platelets in the tumor microenvironment: From solid tumors to leukemia. Biochim Biophys Acta. 2016;1863:392–400.
   PubMed Web of Science ®Google Scholar
• Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126:582–588.
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J Natl Cancer Inst. 2014;106: dju124.
   Google Scholar
• Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol. 2014;23:31–39.
   PubMed Web of Science ®Google Scholar
• Xin-Ji Z, Yong-Gang L, Xiao-Jun S, Xiao-Wu C, Dong Z, Da-Jian Z. The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer: A meta-analysis. Int J Surg. 2015;21:84–91.
   PubMed Web of Science ®Google Scholar
• Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1204–1212.
   PubMed Web of Science ®Google Scholar
• Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016;12:646–653.
   Google Scholar
• Heidland A, Klassen A, Rutkowski P, Bahner U. The contribution of Rudolf Virchow to the concept of inflammation: What is still of importance? J Nephrol. 2006;19:S102–109.
   Google Scholar
• Schmidt A, Weber OF. In memoriam of Rudolf virchow: A historical retrospective including aspects of inflammation, infection and neoplasia. Contrib Microbiol. 2006;13:1–15.
   PubMedGoogle Scholar
• Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4:221–233.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.
   PubMed Web of Science ®Google Scholar
• Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res. 2008;659:15–30.
   PubMed Web of Science ®Google Scholar
• Mikirova N, Casciari J, Rogers A, Taylor P. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med. 2012;10:189.
   PubMed Web of Science ®Google Scholar
• Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer. 2006;42:760–767.
   PubMed Web of Science ®Google Scholar
• Conti I, Dube C, Rollins BJ. Chemokine-based pathogenetic mechanisms in cancer. Novartis Found Symp. 2004;256:29–41.
   PubMedGoogle Scholar
• De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24–37.
   PubMed Web of Science ®Google Scholar
• Mouawad R, Spano JP, Khayat D. Lymphocyte infiltration in breast cancer: A key prognostic factor that should not be ignored. J Clin Oncol. 2011;29:1935–1936.
   Google Scholar
• DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9:212.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. Thrombocytosis as a prognostic marker in gastrointestinal cancers. World J Gastrointest Oncol. 2014;6:34–40.
   PubMed Web of Science ®Google Scholar
• Baranyai Z, Jósa V, Krzystanek M, Eklund AC, Szász AM, Szállási Z. Evaluation of thrombocytosis as predictive factor in colorectal cancer. Magy Seb. 2013;66:331–337.
   PubMedGoogle Scholar
• Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother. 2013;62:471–479.
   PubMed Web of Science ®Google Scholar
• Cedres S, Torrejon D, Martínez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14:864–869.
   PubMed Web of Science ®Google Scholar
• Kaneko M, Nozawa H, Sasaki K, et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy. Oncology. 2012;82:261–268.
   PubMed Web of Science ®Google Scholar
• Seretis C, Gourgiotis S, Gemenetzis G, Seretis F, Lagoudianakis E, Dimitrakopoulos G. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: A pilot study. Am J Surg. 2013;205:691–696.
   PubMed Web of Science ®Google Scholar
• Kocer D, Karakukcu C, Karaman H, Gokay F, Bayram F. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders? Asian Pac J Cancer Prev. 2015;16:3875–3879.
   PubMedGoogle Scholar
• Liu CL, Lee JJ, Liu TP, Chang YC, Hsu YC, Cheng SP. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J Surg Oncol. 2013;107:493–497.
   PubMed Web of Science ®Google Scholar
• Kim JY, Park T, Jeong SH, et al. Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas. Endocrine. 2014;46:526–531.
   PubMed Web of Science ®Google Scholar
• Yaylaci S, Tosun O, Sahin O, et al. Lack of variation in inflammatory hematological parameters between benign nodular goiter and papillary thyroid cancer. Asian Pac J Cancer Prev. 2016;17:2321–2323.
   PubMedGoogle Scholar
• Lang BH, Ng CP, Au KB, Wong KP, Wong KK, Wan KY. Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma? World J Surg. 2014;38:2605–2612.
   PubMed Web of Science ®Google Scholar
• Cho JS, Park MH, Ryu YJ, Yoon JH. The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer. Ann Surg Treat Res. 2015;88:187–192.
   PubMed Web of Science ®Google Scholar
• Liu J, Du J, Fan J, et al. The neutrophil-to-lymphocyte ratio correlates with age in patients with papillary thyroid carcinoma. ORL J Otorhinolaryngol Relat Spec. 2015;77:109–116.
   PubMed Web of Science ®Google Scholar
• Gong W, Yang S, Yang X, Guo F. Blood preoperative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer. Clinics (Sao Paulo). 2016;71:311–314.
   PubMed Web of Science ®Google Scholar
• Baldane S, Ipekci SH, Sozen M, Kebapcilar L. Mean platelet volume could be a possible biomarker for papillary thyroid carcinomas. Asian Pac J Cancer Prev. 2015;16:2671–2674.
   PubMedGoogle Scholar
• Kim SM, Kim EH, Kim BH, et al. Association of the preoperative neutrophil-to-lymphocyte count ratio and platelet-to-lymphocyte count ratio with clinicopathological characteristics in patients with papillary thyroid cancer. Endocrinol Metab (Seoul). 2015;30:494–501.
   PubMedGoogle Scholar